Telomir Pharmaceuticals TELO
NASDAQ TELO
$1.02 +0.01 (+0.99%)
At close: Oct 21, 2026 · 4:00 PM EDT

Telomir Pharmaceuticals (TELO) Non Operating Income (2023 - 2024)

Updated

Telomir Pharmaceuticals (TELO) reported Non Operating Income of $15,445 for Q3 2024, compared with -$757,173 a year earlier.

Analysis

Telomir Pharmaceuticals (TELO) Non Operating Income (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 269.00 Mn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -73.00 Mn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 387.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Telomir Pharmaceuticals 62.66 Mn 42.09 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 15,445.00
Sep 30, 2023 -757,173.00
API Access

Telomir Pharmaceuticals Non Operating Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-income&ticker=TELO&period=max&api_key=YOUR_API_KEY